Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Prothrombin Complex Concentrate
100%
Direct Oral Anticoagulants
100%
Outcome Effect
100%
Management Outcome
100%
Management Effects
100%
Laboratory Effects
100%
Hemostasis
50%
Major Bleeding
37%
30-day Mortality
37%
Thrombin Generation
37%
Urgent Intervention
37%
Dabigatran
25%
Idarucizumab
25%
Clinical Outcomes
25%
Dutch
12%
Blood Samples
12%
Prospective Cohort Study
12%
Thromboembolism
12%
Thromboembolic Complications
12%
Safety Outcomes
12%
Hospitalized Patients
12%
Factor Xa Inhibitors
12%
Hemostatic Agents
12%
Dabigatran Reversal
12%
Reversal Agents
12%
Bleeding Patients
12%
INIS
laboratories
100%
patients
100%
emergencies
100%
management
100%
anticoagulants
100%
prothrombin
100%
mortality
44%
interventions
33%
thrombin
33%
data
11%
blood
11%
safety
11%
hospitals
11%
administration
11%
guidelines
11%
hemostatics
11%
Pharmacology, Toxicology and Pharmaceutical Science
Prothrombin Complex
100%
Direct Oral Anticoagulant
100%
Bleeding
50%
Thromboembolism
50%
Blood Stasis
50%
Thrombin
37%
Dabigatran
37%
Idarucizumab
25%
Prospective Cohort Study
12%
Hemostatic Agent
12%
Blood Clotting Factor 10a Inhibitor
12%
Medicine and Dentistry
Direct Oral Anticoagulant
100%
Prothrombin Complex
100%
Blood Stasis
50%
Thromboembolism
50%
Thrombin
37%
Major Bleeding
37%
Dabigatran
37%
Idarucizumab
25%
Prospective Cohort Study
12%
Hemostat
12%
Bleeding
12%
Blood Clotting Factor 10a Inhibitor
12%